Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.3K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathologie (Heidelberg, Germany)·2026
Same author

Evaluation of prognostic factors and outcomes in primary versus secondary myeloid sarcoma.

Human pathology·2026
Same author

Reply to Bruschi, F.; Casini, G. New Models for the Study of Ocular Toxoplasmosis. Comment on "Ashander et al. Human Retinal Organoid Model of Ocular Toxoplasmosis. <i>Pathogens</i> 2025, <i>14</i>, 286".

Pathogens (Basel, Switzerland)·2026
Same author

Antimicrobial Drug Prophylaxis for Recurrent Ocular Toxoplasmosis.

Pathogens (Basel, Switzerland)·2026
Same author

DNA methylation-based classification of hematolymphoid neoplasms.

Blood advances·2026
Same author

Outer Retinal Disruption in a Young Male.

JAMA ophthalmology·2026
Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Oct 22, 2025

Author Spotlight: Advancing VRL Diagnosis Using Cell-Free DNA Extraction from Vitreous Humor
06:20

Author Spotlight: Advancing VRL Diagnosis Using Cell-Free DNA Extraction from Vitreous Humor

Published on: January 12, 2024

2.2K

Vitreoretinal Lymphoma.

Bianka Sobolewska1, Soon-Phaik Chee2,3,4,5, Fatma Zaguia6

  • 1Center of Ophthalmology, University of Tuebingen, 72076 Tuebingen, Germany.

Cancers
|August 27, 2021
PubMed
Summary
This summary is machine-generated.

Vitreoretinal lymphoma (VRL), a rare aggressive cancer, often progresses to central nervous system lymphoma. Early diagnosis and treatment are crucial for managing this challenging ocular and neurological condition.

Keywords:
CNS lymphomaIL-10/IL-6 ratioMYD88methotrexatevitreoretinal lymphoma

More Related Videos

Application of Optical Coherence Tomography to a Mouse Model of Retinopathy
08:22

Application of Optical Coherence Tomography to a Mouse Model of Retinopathy

Published on: January 12, 2022

4.6K
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

4.0K

Related Experiment Videos

Last Updated: Oct 22, 2025

Author Spotlight: Advancing VRL Diagnosis Using Cell-Free DNA Extraction from Vitreous Humor
06:20

Author Spotlight: Advancing VRL Diagnosis Using Cell-Free DNA Extraction from Vitreous Humor

Published on: January 12, 2024

2.2K
Application of Optical Coherence Tomography to a Mouse Model of Retinopathy
08:22

Application of Optical Coherence Tomography to a Mouse Model of Retinopathy

Published on: January 12, 2022

4.6K
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

4.0K

Area of Science:

  • Ophthalmology
  • Neurology
  • Oncology

Background:

  • Vitreoretinal lymphoma (VRL) is a rare subtype of primary central nervous system lymphoma (PCNSL).
  • VRL primarily affects the retina and vitreous, potentially involving the optic nerve.
  • The disease course is aggressive, with a high risk of progression to CNS lymphoma.

Purpose of the Study:

  • To highlight the diagnostic challenges of VRL, often presenting as nonspecific uveitis.
  • To review current treatment strategies for VRL, particularly in cases of bilateral involvement without CNS disease.
  • To emphasize the need for further research into prophylactic systemic therapies to prevent CNS progression.

Main Methods:

  • Diagnosis relies on anterior chamber or vitreous aspirate biopsy.
  • Treatment considerations include intravitreal chemotherapy (methotrexate, rituximab), systemic high-dose methotrexate, or radiotherapy.
  • The study reviews existing literature and clinical observations regarding VRL management.

Main Results:

  • VRL diagnosis is difficult due to overlapping symptoms with chronic uveitis.
  • Up to 90% of VRL patients develop CNS lymphoma within a year.
  • No established treatment protocol exists for bilateral VRL without CNS involvement.

Conclusions:

  • VRL is an aggressive malignancy requiring prompt diagnosis and management.
  • Intravitreal chemotherapy is a suggested treatment for limited VRL.
  • Further research is essential to confirm the efficacy of systemic therapy in preventing CNS involvement.